COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion ... Early clinical data points to comparable weight reduction between amylin ...

Roche Is Not In Generics, It Is In High-Margin Pharmaceuticals With An Exciting Pipeline This is an important point as generic drugmakers ... that earned >$25.8bn, 2 blockbusters including Ocrevus ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

At that point, Roche can either follow through with the license ... is licensed from AC Immune and has already started two phase 2 trials in Alzheimer’s patients. One in early-stage (prodromal ...

The head of Zealand Pharma has called its $5.3bn partnership with Roche to commercialise an obesity drug with fewer side-effects the “best deal ever”, saying it will help preserve the Danish biotech ...